AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27381900 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 228
Study 24520906 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized brief intervention (CBI)
Number of subjects: 360
Study 24520906 — intervention group
Group type: COMPARATOR
Intervention: In-person brief intervention (IBI)
Number of subjects: 360
Study 22575454 — intervention group
Group type: EXPERIMENTAL
Intervention: Venepuncture
Number of subjects: 607
Study 22575454 — intervention group
Group type: COMPARATOR
Intervention: Heel puncture
Number of subjects: 607
Study 20347307 — intervention group
Group type: EXPERIMENTAL
Intervention: Nolvadex
Number of subjects: 121
Study 20347307 — intervention group
Group type: COMPARATOR
Intervention: generic Tamoxifen (gT)
Number of subjects: 121
Study 17261385 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ventricular fibrillation (VF group)
Number of subjects: 56
Study 17261385 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without clinical ventricular arrhythmias)
Number of subjects: 56
Study 15840042 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolving connectionist systems (ECOS)
Number of subjects: 178
Study 15840042 — intervention group
Group type: COMPARATOR
Intervention: MDRD formula
Number of subjects: 178
Study 11926908 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 78
Study 11926908 — intervention group
Group type: COMPARATOR
Intervention: Adenosine triphosphate disodium, kallidinogenase, and cyanocobalamin (Control)
Number of subjects: 78
Study 10063787 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol/6.25‐mg hydrochlorothiazide (HCTZ)
Number of subjects: 541
Study 10063787 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 541
Study 10063787 — intervention group
Group type: COMPARATOR
Intervention: enalapril
Number of subjects: 541
Study 10063787 — intervention group
Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 541
Study 7586339 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory changes in stenosis-stable segments opposite progressing lesions
Number of subjects: 78
Study 7586339 — intervention group
Group type: EXPERIMENTAL
Intervention: On-trial levels of apolipoprotein B, apo C-III, and blood pressure
Number of subjects: 78
Study 2124033 — intervention group
Group type: COMPARATOR
Intervention: Valproate (1000 mg/day)
Number of subjects: 17
Study 2124033 — intervention group
Group type: EXPERIMENTAL
Intervention: Taltrimide (400 mg/day)
Number of subjects: 17
Study 2124033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 375959 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 17
Study 375959 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 17
Study 30735751 — intervention group
Group type: EXPERIMENTAL
Intervention: Beverage enriched with sulforaphane and glucoraphanin
Number of subjects: 45
Study 28795473 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric Electrical Stimulation (GES) ON
Number of subjects: 21
Study 28795473 — intervention group
Group type: COMPARATOR
Intervention: Gastric Electrical Stimulation (GES) OFF
Number of subjects: 21
Study 25510467 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible catheter
Number of subjects: 30
Study 25510467 — intervention group
Group type: COMPARATOR
Intervention: Stimulating catheter
Number of subjects: 30
Study 24500140 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 154
Study 24500140 — intervention group
Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 154
Study 22362672 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Number of subjects: 26
Study 22362672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 19180516 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamapimod 50 mg
Number of subjects: 0
Study 19180516 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamapimod 150 mg
Number of subjects: 0
Study 19180516 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamapimod 300 mg
Number of subjects: 0
Study 19180516 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) 7.5 mg/week with planned escalation to 20 mg/week
Number of subjects: 0
Study 18156171 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib combined with chemotherapeutic agents
Number of subjects: 57
Study 18156171 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib monotherapy
Number of subjects: 57
Study 15336338 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic pain diary
Number of subjects: 24
Study 15336338 — intervention group
Group type: COMPARATOR
Intervention: Paper pain diary
Number of subjects: 24
Study 11495386 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic interventions for chronic benign pain disorders; specific interventions not detailed.
Number of subjects: 0
Study 9647412 — intervention group
Group type: EXPERIMENTAL
Intervention: ICA+ (internal carotid atherosclerosis)
Number of subjects: 28
Study 9647412 — intervention group
Group type: COMPARATOR
Intervention: ICA- (control group)
Number of subjects: 28
Study 1357864 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone aceponate
Number of subjects: 24
Study 1357864 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednicarbate ointment
Number of subjects: 24
Study 1357864 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone-17-valerate ointment
Number of subjects: 24
Study 3860789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin
Number of subjects: 20
Study 3860789 — intervention group
Group type: COMPARATOR
Intervention: Vaginal prostaglandin E2 gel (4 mg)
Number of subjects: 20
Study 3860789 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal prostaglandin E2 gel (4 mg) in subsequent open study
Number of subjects: 20
Study 30109725 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme for nursing staff on recognising, reporting and managing resident-to-resident elder mistreatment.
Number of subjects: 0
Study 30109725 — intervention group
Group type: COMPARATOR
Intervention: Usual standard care (Control group)
Number of subjects: 0
Study 29705218 — intervention group
Group type: EXPERIMENTAL
Intervention: BH4 (Kuvan; BioMarin Pharmaceutical Inc)
Number of subjects: 17
Study 29705218 — intervention group
Group type: COMPARATOR
Intervention: PLC (Placebo)
Number of subjects: 17
Study 27897608 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% watermelon juice
Number of subjects: 0
Study 27897608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24866715 — intervention group
Group type: EXPERIMENTAL
Intervention: Siblings' Survival Calendar (SSC)
Number of subjects: 0
Study 22492370 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tomato-based diet (equivalent to 32-50 mg lycopene/d)
Number of subjects: 225
Study 22492370 — intervention group
Group type: EXPERIMENTAL
Intervention: Control diet supplemented with lycopene capsules (10 mg/d)
Number of subjects: 225
Study 22492370 — intervention group
Group type: COMPARATOR
Intervention: Control diet (low in tomato-based foods)
Number of subjects: 225
Study 20045613 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair for PAA
Number of subjects: 0
Study 20045613 — intervention group
Group type: COMPARATOR
Intervention: Open repair for PAA
Number of subjects: 0
Study 17468572 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact exercise regimen (supervised, progressive, 2-3 times per week plus home program)
Number of subjects: 120
Study 15149909 — intervention group
Group type: EXPERIMENTAL
Intervention: Purchase of Services (POS) benefit supplementing usual geriatric care management
Number of subjects: 541
Study 12375212 — intervention group
Group type: EXPERIMENTAL
Intervention: New intervention in rehabilitation medicine
Number of subjects: 0
Study 12375212 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 9657623 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 12
Study 9657623 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 12
Study 7762493 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil 180 mg
Number of subjects: 278
Study 7762493 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil 360 mg
Number of subjects: 278
Study 7762493 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil 540 mg
Number of subjects: 278
Study 7762493 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 278
Study 2150678 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 0
Study 2150678 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study 538086 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 10
Study 538086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31276312 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC-HA mouthrinse
Number of subjects: 75
Study 31276312 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (CHX) mouthrinse
Number of subjects: 75
Study 31276312 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 75
Study 31299617 — intervention group
Group type: EXPERIMENTAL
Intervention: Se-rich lentils (55 μg Se/day)
Number of subjects: 405
Study 31299617 — intervention group
Group type: COMPARATOR
Intervention: Control lentils (1.5 μg Se/day)
Number of subjects: 405
Study 28467661 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g of supplemental elemental calcium daily
Number of subjects: 193
Study 28467661 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g of supplemental elemental calcium daily
Number of subjects: 193
Study 28467661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 28467661 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher milk intakes
Number of subjects: 193
Study 28467661 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 193
Study 28467661 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 193
Study 28467661 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher alcohol consumption
Number of subjects: 193
Study 25888263 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/day
Number of subjects: 1717
Study 25888263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1717
Study 23883186 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (QIV)
Number of subjects: 4659
Study 23883186 — intervention group
Group type: COMPARATOR
Intervention: Inactivated trivalent influenza vaccine (TIV)
Number of subjects: 4659
Study 22159929 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 40
Study 22159929 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (TT)
Number of subjects: 40
Study 19806797 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-phase leukocyte filtration (Group 1)
Number of subjects: 40
Study 19806797 — intervention group
Group type: EXPERIMENTAL
Intervention: Single leukocyte filter with continuous leukofiltration (Group 2)
Number of subjects: 40
Study 19806797 — intervention group
Group type: EXPERIMENTAL
Intervention: Single leukocyte filter with strategic leukofiltration (Group 3)
Number of subjects: 40
Study 16915750 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 40
Study 16915750 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 40
Study 15579516 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg (A300)
Number of subjects: 12
Study 15579516 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg (V160)
Number of subjects: 12
Study 15579516 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Aliskiren 150 mg and Valsartan 80 mg (A150+V80)
Number of subjects: 12
Study 15579516 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study 11448404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac catheterization
Number of subjects: 61232
Study 11448404 — intervention group
Group type: COMPARATOR
Intervention: Age ≤49 years
Number of subjects: 61232
Study 9150521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutured procedure
Number of subjects: 110
Study 9150521 — intervention group
Group type: COMPARATOR
Intervention: Nonsutured procedure
Number of subjects: 110
Study 7982765 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria group (n=43)
Number of subjects: 43
Study 7982765 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched, n=33)
Number of subjects: 43
Study 2736402 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine (100 mg/kg)
Number of subjects: 0
Study 2736402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30316955 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder training group (clamping prior to catheter removal)
Number of subjects: 218
Study 30316955 — intervention group
Group type: COMPARATOR
Intervention: Free drainage removal group
Number of subjects: 218
Study 30316955 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with prostatism under medication
Number of subjects: 218
Study 31952657 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (i.p.) chemotherapy
Number of subjects: 0
Study 31952657 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal (i.p.) cisplatin and i.p. carboplatin
Number of subjects: 0
Study 31952657 — intervention group
Group type: COMPARATOR
Intervention: Dose-dense i.v. paclitaxel and carboplatin
Number of subjects: 0
Study 25928699 — intervention group
Group type: EXPERIMENTAL
Intervention: Samidorphan (3-carboxamido-4-hydroxynaltrexone)
Number of subjects: 24
Study 25928699 — intervention group
Group type: COMPARATOR
Intervention: Placebo (day 1)
Number of subjects: 24
Study 25928699 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 24
Study 23879944 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg loading dose prior to PCI followed by 20 mg Tid after PCI)
Number of subjects: 106
Study 23879944 — intervention group
Group type: COMPARATOR
Intervention: Control (standard therapy)
Number of subjects: 106
Study 21924015 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacteria (one capsule per time, for 7 days)
Number of subjects: 81
Study 21924015 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bifidobacteria)
Number of subjects: 81
Study 19737963 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (4 grams/day oral)
Number of subjects: 26
Study 16718762 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation of ranitidine
Number of subjects: 20
Study 16718762 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation of ranitidine
Number of subjects: 20
Study 16718762 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation of bismuth
Number of subjects: 20
Study 16718762 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation of bismuth
Number of subjects: 20
Study 15572534 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP 50 microg
Number of subjects: 25
Study 15572534 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP 100 microg
Number of subjects: 25
Study 15572534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 11529353 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipelle
Number of subjects: 30
Study 11529353 — intervention group
Group type: COMPARATOR
Intervention: Fractional curettage
Number of subjects: 30
Study 9215608 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA oral suspension at a daily dose of 1000 mg for 12 weeks
Number of subjects: 279
Study 9215608 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 279
Study 7968417 — intervention group
Group type: EXPERIMENTAL
Intervention: ART group (N = 12)
Number of subjects: 12
Study 7968417 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT group (N = 5)
Number of subjects: 12
Study 7968417 — intervention group
Group type: COMPARATOR
Intervention: CON group (N = 8; age = 25.4 ± 2.4 yr)
Number of subjects: 12
Study 2940334 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin (HBIG) - 3 or 4 doses in different schedules
Number of subjects: 111
Study 2940334 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (Hevac‐B) - 1 dose at birth, 1, 2, and 12 months
Number of subjects: 111
Study 2940334 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (Hevac‐B) - 1 dose at birth, 1, 2, and 12 months + HBIG - 1 dose at birth
Number of subjects: 111
Study 29655772 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 75, 150, 300 mg (6 × 4 weekly injections)
Number of subjects: 642
Study 29655772 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 75, 150, 300 mg (3 × 4 weekly injections)
Number of subjects: 642
Study 29655772 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg (6 × 4 weekly injections)
Number of subjects: 642
Study 29655772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642
Study 28095549 — intervention group
Group type: EXPERIMENTAL
Intervention: SSR (mass market topical products)
Number of subjects: 18
Study 28095549 — intervention group
Group type: COMPARATOR
Intervention: NFL (non-ablative fractional laser)
Number of subjects: 18
Study 23810681 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 16
Study 23810681 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone 40 mg
Number of subjects: 16
Study 23232292 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (group 2A)
Number of subjects: 131
Study 23232292 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (group 2B)
Number of subjects: 131
Study 23232292 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (group 3A)
Number of subjects: 131
Study 23232292 — intervention group
Group type: COMPARATOR
Intervention: No recanalization therapy (group 3B)
Number of subjects: 131
Study 23232292 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (overall)
Number of subjects: 131
Study 23232292 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic intracerebral hemorrhage (SICH)
Number of subjects: 131
Study 22171147 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide
Number of subjects: 11
Study 22171147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 17904278 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical prilocaine-lidocaine cream combined with periprostatic nerve block (PNB)
Number of subjects: 300
Study 17904278 — intervention group
Group type: COMPARATOR
Intervention: Periprostatic nerve block (PNB) alone
Number of subjects: 300
Study 16925853 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quercetin soup (69 mg total quercetin)
Number of subjects: 0
Study 16925853 — intervention group
Group type: COMPARATOR
Intervention: Low-quercetin soup (5 mg total quercetin)
Number of subjects: 0
Study 16925853 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quercetin soup
Number of subjects: 0
Study 12955551 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole 200 mg
Number of subjects: 10
Study 12955551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10732657 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 243
Study 10732657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 8633830 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (0.03 mg/kg of body weight) given three times a week for 6 months
Number of subjects: 52
Study 8633830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 8633830 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone
Number of subjects: 52
Study 1296992 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education and counseling independent of clinic staff
Number of subjects: 40
Study 1296992 — intervention group
Group type: COMPARATOR
Intervention: Health education and counseling from clinic staff
Number of subjects: 40
Study 6396971 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvinylpyridine N-oxide (PVNO) infusion, 300-400 mg per kg bodyweight, administered in intervals of one to two years
Number of subjects: 28
Study 31036041 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (benefit-inform)
Number of subjects: 80
Study 31036041 — intervention group
Group type: COMPARATOR
Intervention: Group B (side effect-inform)
Number of subjects: 80
Study 29262859 — intervention group
Group type: EXPERIMENTAL
Intervention: Danshen extract (DanshenDuofensuanyan injection and Danshen drop spill)
Number of subjects: 156
Study 29262859 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 156
Study 29262859 — intervention group
Group type: EXPERIMENTAL
Intervention: Danshen extract
Number of subjects: 156
Study 25728021 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV-C treatment
Number of subjects: 24
Study 25728021 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 24
Study 24002945 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg every 3 weeks plus carboplatin + paclitaxel for maximum of six cycles, followed by single-agent bevacizumab until disease progression
Number of subjects: 198
Study 22109566 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie method in addition to the first-line care
Number of subjects: 148
Study 22109566 — intervention group
Group type: COMPARATOR
Intervention: First-line Care Group (recommended first-line care alone)
Number of subjects: 148
Study 20128355 — intervention group
Group type: EXPERIMENTAL
Intervention: AS-MQ-PQ
Number of subjects: 50
Study 20128355 — intervention group
Group type: COMPARATOR
Intervention: AS-MQ
Number of subjects: 50
Study 17389753 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor mould removal, fungicide application, and fan installation in loft; duration not specified.
Number of subjects: 182
Study 15181994 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential path-length spectroscopy (DPS) on cancerous bronchial mucosa
Number of subjects: 0